

## Vermont Vaccine Purchasing Pool Assessment Calculation Worksheet

Column →	A	B	C	D	E	F	G
	CHILDREN			ADULTS			
Line ↓	Prior	2017		Prior	2017		Comments
<b>A. Preliminary Vaccine Cost Estimates</b>							
01.	14,176,557	15,327,490		2,382,346	1,981,498		Est. costs of vaccines (sheets e & f with utiliz. & price adj.)
02.	-7,474,867	-8,477,222	VFC	-390,377	-338,378	\$317	Estimated VFC Award & Other Federal Grants
03.	0	0		0	0		Other
04.	6,701,690	6,850,268	6,850,268	1,991,969	1,643,120	1,643,120	Estimated VVPP Vaccine costs
05.	167,542		171,257	49,799		41,078	VDH administrative fee
06.	793,475		793,475	263,085		263,085	CDC Advance Funding Amortization (sheet d.)
07.	-1,291,443		-674,169 <sup>1</sup>	-290,145		-113,293 <sup>1</sup>	Vaccine Fund carryforward (sheet d.)
09.	6,371,263		7,140,830	2,014,708		1,833,990	
<b>B. Assessable Covered Lives Estimates</b>							
11.	57,603		57,990	339,939		360,433	Assessable Covered Lives (sheet c)
12.	1.50%		1.50%	1.50%		1.50%	Leakage (unknown insurer, out of reach entity, etc.)
19.	56,739		57,120	334,840		355,027	Assessable lives actually paying
<b>C. Planning / budgeting parameters</b>							
21.	0.01%		0.01%	1.50%		1.50%	Provision for vaccine utilization increase
22.	4.80%		4.80% <sup>2</sup>	3.65%		3.65% <sup>2</sup>	Provision for vaccine cost increase
23.	0.25%		0.25%	0.25%		0.25%	Bad debt allowance (as a % of funds to be remitted)
24.	2.50%		2.50%	2.50%		2.50%	VDH administrative fee
25.	3.0		3.0	3.0		3.0	Working Capital Reserve as months of ave. Line 09 amount
26.	50.00%		50.00%	50.00%		50.00%	% of reserve to build in future years
27.	0.00%		0.00%	0.00%		0.00%	Other reserves as allowed by law & deemed prudent
<b>D. Assessment Calculation</b>							
31.	\$ 6,371,263		\$ 7,140,830	\$ 2,014,708		\$ 1,833,990	(a) Estimated total non-federal cost (adjusted)
32.	119,964	137,231		37,935	35,246		Total Administrative Budget (from sheet b.)
33.	15,928	17,852		5,037	4,585		Bad Debt Allowance
34.	135,892	155,083	155,083	42,972	39,831	39,831	(b) part 1 - Anticipated Operating Costs
35.	796,408		892,604	251,839		229,249	(b) part 2 - Working Capital Reserve buildup
36.	0		0	0		0	(c) part 3 - Other Reserves
39.	\$ 7,303,563		\$8,188,517	\$ 2,309,519		\$2,103,070	Total Assessment Billed
<b>E. Per Assessable Covered Life Assessment</b>							
41.	\$128.72		\$143.36	\$6.90		\$5.92	Annual Assessment per covered life
42.	\$10.73		\$11.95	\$0.58		\$0.50	Monthly Assessment per covered life calculated
43.	\$10.73		\$11.95	\$0.58		\$0.50	Monthly Assessment per covered life recommended
<b>F. Financial Carry Forwards</b>							
51.	812,336		910,456 <sup>3</sup>	256,876		233,834 <sup>3</sup>	Unexpended assessments
<b>G. Various Performance Metrics</b>							
61.	1.79%		2.00%	1.90%		2.15%	Net admin costs as % of vaccine costs
62.	4.53%		4.76%	4.66%		4.92%	Lines 6 + 34 as % of vaccines
63.	-7.58%		11.37%	-30.95%		-13.79%	% year to year change in assessment rate
64.	\$ 10.29		\$10.47 <sup>4</sup>	\$0.52		\$0.40 <sup>4</sup>	"Normalized" assessment rate (w/o lines 7, 8, & 35)
<b>H. Vaccine Cost per Covered Life determination</b>							
71.	\$ 9.70		\$ 9.84	\$ 0.49		\$ 0.38	Vaccine Cost Calculated
72.	\$ 9.70		\$ 9.84	\$ 0.49		\$ 0.38	Vaccine Cost recommended

**Notes:**

- <sup>1</sup> Based upon best available estimates pending implementation of full VVPP accounting system over the next year.
- <sup>2</sup> The provision for cost increases is applied for 6 months for childhood vaccines and 3 months for adult vaccines in developing the line 01. cost estimates. (This is due to the respective contract change dates, i.e. 4/1 for childhood vaccines and 7/1 for adult vaccines.)
- <sup>3</sup> Carryforward cash amounts, if any, will be applied first to repay amounts required to meet the federal CDC's advance funding requirement and then to reduce future assessments. (See, for example, Line 08.)
- <sup>4</sup> This calculation gives an indication of what the VT assessment rates would have been for a mature program this year (i.e., without reserve changes).

**VT DOH Pediatric Vaccine Purchase Estimates  
Federal Fiscal Year 17**

Column →  
Line ↓

	A	B	C	D	E	F	G	H	I
	Vaccine	Brand Name	NDC	Prior Year Cost Per Dose	Prior Year Actual Doses Distributed	Prior Year Actual Cost	VVPP Cost Per Dose <sup>1</sup>	Total Estimated Doses	Total Estimated Cost
01.	DTaP	Daptacel	49281-0286-10	\$16.04	220	\$3,598	\$16.73	790	\$13,217
02.		Infanrix	58160-0810-11	\$16.15	6,400	\$105,621	\$16.85	9,600	\$161,760
03.	DTaP-HepB-IPV	Pediarix	58160-0811-52	\$53.86	12,690	\$689,817	\$54.90	13,630	\$748,287
04.	DTaP-IPV/Hib	Pentacel	49281-0510-05	\$54.38	4,490	\$249,606	\$56.91	4,250	\$241,868
05.	DTaP-IPV	Kinrix	58160-0812-11	\$38.50	6,490	\$253,963	\$39.57	6,740	\$266,702
06.	Hib	ActHIB	49281-0545-05	\$9.45	18,220	\$173,066	\$9.55	21,570	\$205,994
07.		PedvaxHIB	00006-4897-00	\$12.34	0	\$0	\$12.48	0	\$0
08.	Hib-Men CY	MenHibrix	58160-0801-11	\$10.10	0	\$0	\$10.53	0	\$0
09.	HepA	Vaqta	00006-4831-41	\$17.40	0	\$0	\$18.23	0	\$0
10.		Havrix	58160-0825-11	\$17.01	21,350	\$372,659	\$17.83	17,530	\$312,560
11.	HepB	Recombivax	00006-4981-00	\$11.75	0	\$0	\$12.30	0	\$0
12.		Engerix B	58160-0820-11	\$11.08	7,790	\$88,357	\$11.60	7,180	\$83,288
13.	HPV	(HPV9) Gardasil	00006-4119-03	\$134.26	23,860	\$3,262,243	\$141.60	27,650	\$3,915,240
14.	IPV	IPOLE	49281-0860-10	\$12.58	2,780	\$35,187	\$12.72	3,150	\$40,068
15.	Influenza	Fluzone - Quad	49281-0625-15	\$13.15	23,000	\$302,450	\$13.77	25,350	\$349,070
16.			49281-0516-25	\$17.940	12,000	\$215,280	\$19.143	16,000	\$306,288
17.			49281-0416-50	\$15.10	0	\$0	\$14.925	17,900	\$267,158
18.			49281-0416-10	\$18.88	5,000	\$75,500	\$15.818	4,550	\$71,972
19.		Fluarix - Quad	58160-0905-52	0	0	\$0	\$14.430	1,200	\$17,316
20.		FluMist - Quad	66019-0302-10	\$18.88	26,000	\$490,880	\$0	0	\$0
21.	MMR	MMR II	00006-4681-00	\$19.90	7,030	\$140,714	\$20.11	7,730	\$155,450
22.	MMRV	ProQuad	00006-4171-00	\$109.01	6,860	\$767,459	\$114.25	7,160	\$818,030
23.	MCV4	Menaqtra	49281-0589-05	\$84.95	13,765	\$1,206,785	\$89.16	10,790	\$962,036
24.		Menveo	46028-0208-01	\$83.56	220	\$17,577	\$68.32	340	\$23,229
25.	MENB	Trumenba	00005-0100-10	\$95.75	0	\$0	\$95.75	0	\$0
26.		Bexsero	46028-0114-02	\$122.95	3,330	\$385,961	\$98.51	4,230	\$416,697
27.	PCV13	Prevnar 13	00005-1971-02	\$116.91	23,260	\$2,758,372	\$120.39	27,480	\$3,308,317
28.	PPSV23	Pneumovax 23	00006-4943-00	\$43.98	112	\$5,095	\$46.40	230	\$10,672
29.	RV	(RV5) RotaTeq	00006-4047-41	\$63.96	380	\$24,659	\$66.49	730	\$48,538
30.		(RV1) Rotarix	58160-0854-52	\$85.04	10,370	\$890,517	\$86.75	13,720	\$1,190,210
31.	Td	Tenivac	49281-0215-10	\$18.82	531	\$10,251	\$19.69	690	\$13,586
32.	Tdap	Boostrix	58160-0842-11	\$31.25	7,520	\$235,748	\$31.37	6,880	\$215,826
33.		Adacel	49281-0400-10	\$31.37	1,540	\$48,310	\$31.37	1,110	\$34,821
34.	VAR	Varivax	00006-4827-00	\$83.77	7,600	\$655,983	\$88.34	8,700	\$768,558

41.				Totals:	252,808	\$13,465,657		266,880	\$14,966,755
42.								Adjusted for utilization Increase	\$14,968,252
43.								Further adjusted for price increase	\$15,327,490
51.		VFC award		<u>Dollars</u>	\$8,477,222	<u>%</u>	55.31%		-\$8,477,222

Notes:

<sup>1</sup> CDC pediatric vaccine contract purchase prices as of 9/1/16

**VT DOH Adult Vaccine Purchase Estimates  
Federal Fiscal Year 17**

Column →  
Line ↓

	A	B	C	D	E	F	G	H	I	
	Vaccine	Brand Name	NDC	Prior Year Cost Per Dose	Prior Year Actual Doses Distributed	Prior Year Actual Cost	VVPP cost per dose <sup>1</sup>	Total Estimated Doses	Total Estimated Cost	
01.	HepA	Vaqta	00006-4096-02	\$25.73	0	\$0	\$27.68	0	\$0	
02.		Havrix	58160-0826-11	\$25.73	3,170	\$81,564	\$25.73	4,610	\$118,615	
03.	HepB	Recombivax	00006-4995-41	\$27.73	0	\$0	\$23.78	0	\$0	
04.		Engerix B	58160-0821-11	\$24.16	3,920	\$95,877	\$25.33	2,620	\$66,365	
05.	HepA-HepB	Twinrix	58160-0815-52	\$54.32	1,090	\$63,136	\$54.66	1,900	\$103,854	
06.	HPV	(HPV9) Gardasil	00006-4119-03	\$121.64	1,350	\$161,276	\$119.04	1,680	\$199,987	
08.	HZV	Zostavax	00006-4963-41	\$117.59	5,030	\$589,800	\$117.12	6,070	\$710,918	
09.	Influenza	Fluarix	58160-0905-52	\$0.00	0	\$0	\$12.72	400	\$5,088	
10.		FluLaval	19515-0898-11	\$11.40	1,500	\$17,100	\$0.00	0	\$0	
11.	MMR	MMR II	00006-4681-00	\$40.97	80	\$3,210	\$40.00	170	\$6,800	
12.	MCV4	Menactra	49281-0589-05	\$75.634	210	\$15,656	\$74.334	200	\$14,867	
13.		Menveo	46028-0208-01	\$71.65	5	\$358	\$72.45	10	\$725	
14.	MENB	Trumenba	00005-0100-10	\$85.72	0	\$0	\$85.54	0	\$0	
15.		Bexsero	46028-0114-02	\$122.35	30	\$3,612	\$117.49	110	\$12,924	
16.	PCV13	Prevnar 13	00005-1971-02	\$96.13	490	\$47,142	\$96.56	510	\$49,246	
17.	PPSV23	Pneumovax 23	00006-4943-00	\$26.59	5,581	\$146,968	\$26.15	5,490	\$143,564	
18.	Td	Tenivac	49281-0215-10	\$14.419	2,460	\$30,786	\$12.271	2,000	\$24,542	
19.	Tdap	Boostrix	58160-0842-11	\$23.45	15,620	\$369,664	\$24.39	16,080	\$392,191	
20.		Adacel	49281-0400-10	\$23.45	3,770	\$88,661	\$23.724	3,270	\$77,577	
	VAR	Varivax	00006-4827-00	\$68.20	60	\$4,018	\$66.36	110	\$7,300	
21.					Totals:	44,366	\$1,718,828	45,230	\$1,934,562	
22.									Adjusted for utilization increase	\$1,963,581
29.									Further adjusted for price increase	\$1,981,498
31.									<u>Dollars</u>	<u>%</u>
					Estimated 317 Funding	\$338,378	17.08%			-\$338,378

<sup>1</sup> CDC adult vaccine contract purchase prices as of 9/1/16

## Prior Year's Financial Recap

Column →	A	B	C
Line ↓			
Revenues			
01.	Carryforward from prior year	\$0.00	
02.	VVPP assessment collections over federal fiscal year	\$9,845,367.53	
03.	317 grant funds received	\$369,077.83	
04.	Medicaid payments (will be in Line 02. in future)	\$640,302.84	
05.	VFC (including VFC flu)	\$7,747,282.65	
06.			
07.			
08.			
09.			\$18,602,030.85
Expenditures / Allowances			
21.	State bulk purchase	\$6,810,449.50	
22.	State Flu	\$438,552.55	
23.	State direct ship	\$1,080,774.40	
24.	VFC (including VFC flu) vaccine purchases	\$7,747,282.65	
25.	KidsVax <sup>1</sup>	\$94,530.77	
26.	VDH administration fee	\$217,341.00	
27.	Year 2 of 3 of initial cash amortization	\$1,056,559.94	
28.	317 program vaccine purchases	\$369,077.83	
29.			<u>-\$17,814,568.64</u>
98.	Vaccine Fund Carryforward <sup>2</sup> (applied to reduce this year's assessment)		<u>\$787,462.21</u>
		<u>Child</u>	<u>Adult</u>
99.	Year 3 of 3 of initial cash amortization <sup>3</sup>	\$793,474.76	263,085

**Notes:**

<sup>1</sup> Full amount of KidsVax contract through 12/31/2016 net of amounts paid earlier.

<sup>2</sup> Excess of Revenues (including prior carryforward) over Expenditures.

<sup>3</sup> Stipulated recovery amount payable over 3 years (see 2015 Assessment Setting worksheet).  
2017 is the last year of this amortization.